The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures
Summit Therapeutics PLC (LON:SUMM; NASDAQ:SMMT) said that its PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (DMD).
The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures.
Summit added that it would now focus its operations on the development of its pipeline of new mechanism antibiotics, with its lead product candidate, ridinilazole, expected to enter Phase 3 clinical trials for the treatment of C. difficile infection in the first quarter of 2019.
The company also said it would investigate whether information gathered as part of PhaseOut DMD phase 2 clinical trial could be made available to support other research activities in DMD for the benefit of the DMD community.
The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures.
Summit added that it would now focus its operations on the development of its pipeline of new mechanism antibiotics, with its lead product candidate, ridinilazole, expected to enter Phase 3 clinical trials for the treatment of C. difficile infection in the first quarter of 2019.
The company also said it would investigate whether information gathered as part of PhaseOut DMD phase 2 clinical trial could be made available to support other research activities in DMD for the benefit of the DMD community.
